Routine officer appointment with no immediate trading implications. Monitor for the $15M+ capital raise trigger for the severance plan, which could signal future equity dilution.
Price Chart
Executive Summary
Retension Pharmaceuticals appointed Robert Wong as Vice President, Chief Accounting Officer (Principal Accounting Officer), effective November 2, 2026. This is a routine addition to the finance leadership team — Wong brings relevant biotech and Big 4 experience — but carries no material financial or operational implications for the company.
Key Facts
- Robert Wong appointed VP, Chief Accounting Officer effective November 2, 2026
- Annual base salary of $360,000
- Target bonus of 30% of base salary
- Sign-on bonus of $20,000 contingent on employment through March 31, 2027
- Stock option award for 25,000 shares vesting over 4 years (25% cliff at 1 year, then monthly)
- Eligible for Executive Change in Control and Severance Plan (contingent on $15M+ capital raise)
- Wong previously served as VP & CAO at Cytokinetics (CYTK) and Controller & CAO at Genentech
Financial Impact
No material financial impact. Compensation package is standard for a mid-cap biotech CAO role.
Risk Factors
- No material risks identified from this filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-111794 |
| Document: ea0309450-8k_retension.htm | 0001213900-26-111794 |
| Document: 0001213900-26-111794-index-headers.html | 0001213900-26-111794 |
| Document: 0001213900-26-111794-index.html | 0001213900-26-111794 |
| Document: 0001213900-26-111794.txt | 0001213900-26-111794 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 3d ago | 8-K | $16.55 | awaiting T+5 | — | $14.55 (−12.11%) |
Oct 16, 2026 9d ago | SC 13G | $16.33 | awaiting T+5 | — | $14.55 (−10.93%) |
Oct 16, 2026 10d ago | SC 13G | $14.07 $15.25 | ▲ +8.39% | ▲ +8.82% | $14.55 (+3.38%) |
Oct 15, 2026 11d ago | SC 13G | $12.21 $15.50 | ▲ +26.95% | ▲ +27.96% | $14.55 (+19.12%) |
Oct 14, 2026 11d ago | SC 13D | $12.21 $15.50 | ▲ +26.95% | ▲ +27.96% | $14.55 (+19.12%) |
Oct 13, 2026 12d ago | Insider Cluster | $11.64 $15.00 | ▲ +28.87% | ▲ +28.41% | $14.55 (+24.96%) |
Oct 13, 2026 12d ago | 3 | $11.64 $15.00 | ▲ +28.87% | ▲ +28.41% | $14.55 (+24.96%) |
Oct 9, 2026 16d ago | 424B4 | $11.32 $16.33 | ▲ +44.26% | ▲ +45.75% | $14.55 (+28.49%) |
Oct 9, 2026 17d ago | EFFECT | $10.53 $14.07 | ▲ +33.62% | ▲ +35.59% | $14.55 (+38.13%) |
Oct 8, 2026 17d ago | 3 | $10.53 $14.07 | ▲ +33.62% | ▲ +35.59% | $14.55 (+38.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers